Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2023 07:58 ET | Source: Recursion Pharmaceuticals

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion’s proprietary...
November 02, 2023 08:05 ET | Source: Recursion Pharmaceuticals

Recursion to Participate in Upcoming Investor Conference

SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
September 05, 2023 16:30 ET | Source: Recursion Pharmaceuticals

Recursion to Participate in Upcoming Investor Conferences

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
September 05, 2023 07:59 ET | Source: Recursion Pharmaceuticals

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
August 08, 2023 08:00 ET | Source: Recursion Pharmaceuticals

Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
August 08, 2023 07:58 ET | Source: Recursion Pharmaceuticals

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein interactions for approximately 36 billion compounds in the Enamine REAL Space, reported to be the world’s...
August 01, 2023 08:30 ET | Source: Recursion Pharmaceuticals

Recursion to Participate in Upcoming Investor Conference

SALT LAKE CITY, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
July 26, 2023 18:58 ET | Source: Recursion Pharmaceuticals

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at...
July 13, 2023 02:51 ET | Source: Recursion Pharmaceuticals

Recursion kündigt Zusammenarbeit und Investition in Höhe von 50 Millionen USD von NVIDIA zur Beschleunigung bahnbrechender Modelle für die KI-gestützte Wirkstoffforschung an

SALT LAKE CITY, TORONTO und MONTRÉAL, July 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), ein führendes, im klinischen Stadium tätiges TechBio-Unternehmen, das die Biologie dekodiert,...
July 13, 2023 02:51 ET | Source: Recursion Pharmaceuticals

Recursion annonce sa collaboration avec NVIDIA qui investit 50 millions de dollars pour l'accélération de la mise au point de d'innovants modèles de base dans la découverte de médicaments basée sur l'IA

SALT LAKE CITY, TORONTO et MONTRÉAL, 13 juill. 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), société biotechnologique au stade clinique chef de file dans le décodage biologique pour...